Universal screening for HCV infection is cost-effective
December 6, 2018
Study suggests all adults age 18 and older should be screened for HCV.
Mark L. Fuerst
Half of hepatitis C patients can receive shorter direct-acting antiviral treatments
December 6, 2018
Shorter treatment could significantly reduce costs of therapy.
Too few young opioid drug users tested for hepatitis C infection
November 6, 2018
Effective direct-acting antivirals are available for teens.
Hepatitis C drug treatments effective for inject drug users
November 6, 2018
Strong evidence supports removal of restrictions to direct-acting antiviral therapy based on recent drug use.
Transplanting Hepatitis C-infected kidneys is cost-effective and safe
October 3, 2018
Two studies show these kidneys could be valuable resource for patients in need
Drug addicts face barriers that prevent Hepatitis C treatment
October 3, 2018
New approaches are needed for physicians to engage young people who inject drugs
Hepatitis C epidemic hides within opioid use epidemic
September 4, 2018
An urgent call to action to treat combined epidemics
Hepatitis C virus eradication by direct-acting antiviral agents improves glucose tolerance
September 4, 2018
Glucose tolerance is an independent predictor of overall mortality and hepatic decompensation in patients with HCV cirrhosis.
Two-drug direct-acting antiviral combination treats advanced liver disease
August 8, 2018
Ledipasvir/sofosbuvir is safe and effective for hepatitis C virus patients who fail on simeprevir/ sofosbuvir.
Direct-acting antiviral combination effective in hard-to-treat hepatitis C virus genotype 3
August 7, 2018
Real-world study shows efficacy of sofosbuvir/velpatasvir for 12 weeks
